Vaxcyte: announces positive topline data for VAX-31 from phase 3 OPUS-1

What happened On Oct 5, 2026, Vaxcyte issued a press release announcing positive topline data from its Phase 3 OPUS-1 pivotal adult trial evaluating the safety, tolerability and immunogenicity of VAX-31, the company’s 31-valent pneumococcal conjugate vaccine candidate to prevent invasive pneumococcal disease and pneumococcal pneumonia. The press release was attached as Exhibit 99.1 to the Form 8-K. The company also made a slide presentation available, attached as Exhibit 99.2.

Key details

• Date filed: Oct 5, 2026.
• Trial: phase 3 OPUS-1 pivotal adult trial.
• Product: VAX-31, a 31-valent pneumococcal conjugate vaccine candidate.
• Materials: press release (Exhibit 99.1) and slide presentation (Exhibit 99.2) made available.

Why it may matter The filing reports Item 7.01 (Regulation FD disclosure), which covers the company issuing the press release about trial results, and Item 8.01 (Other events), which covers the slide presentation being made available. A filing does not show why the insider traded or why the company acted.